The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab (Janssen’s Stelara) has been challenged by novel, highly effective IL-17 and IL-23 inhibitors. In particular, the uptake of risankizumab (AbbVie’s Skyrizi)—the latest IL-23 inhibitor to be approved for psoriasis—has been phenomenal, raising an alarm for other approved biologics. The recent and expected approvals of bimekizumab, an IL-17 inhibitor; deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor; and the nonsteroidal topical agents roflumilast and tapinarof will further increase the number of psoriasis treatments and make the market even more competitive.
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 31 country-specific interviews with thought leaders. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Total diagnosed prevalence of psoriasis by country, segmented by mild and moderate to severe subpopulations.
Emerging therapies: Phase III/PR: 6 drugs; Phase II: 9 drugs; coverage of select preclinical and Phase I products.
Forecast: 10-year, annualized, drug-level sales and patient share of key psoriasis therapies through 2030, segmented by brands/generics and epidemiological subpopulations.